Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8895601 | JANSSEN BIOTECH | Pyrazolyl quinoxaline kinase inhibitors |
May, 2031
(8 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9464071 | JANSSEN BIOTECH | Pyrazolyl quinoxaline kinase inhibitors |
Apr, 2031
(8 years from now) | |
US9902714 | JANSSEN BIOTECH | Quinoxaline derivatives useful as FGFR kinase modulators |
Mar, 2035
(12 years from now) | |
US10898482 | JANSSEN BIOTECH | Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
Feb, 2036
(13 years from now) | |
US11077106 | JANSSEN BIOTECH | Cancer treatment |
Feb, 2038
(15 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Apr 12, 2024 |
NCE-1 date: April, 2023
Market Authorisation Date: 12 April, 2019
Treatment: Treatment of adults with locally advanced or metastatic urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemotherapy; Treatment of adults with locally advanced or metastatic, surgically unresectable urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemotherapy; Treatment of adults with metastatic urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemotherapy; Treatment of adults with locally advanced or metastatic urothelial carcinoma that has susceptible fgfr3 genetic alterations and progressed during or following prior platinum-containing chemotherapy; Treatment of adults with locally advanced or metastatic urothelial carcinoma with susceptible fgfr3 or fgfr2 genetic alterations, and progressed during or following prior platinum-containing chemotherapy, with dosing based on serum phosphate levels
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic